33860663|t|Neuroprotective Efficacy of Co-Encapsulated Rosiglitazone and Vorinostat Nanoparticle on Streptozotocin Induced Mice Model of Alzheimer Disease.
33860663|a|Anomalies in brain insulin signaling have been demonstrated to be involved in the pathology of Alzheimer disease (AD). In this context, the neuroprotective efficacy of an insulin sensitizer, rosiglitazone, has been confirmed in our previous study. In the present study, we hypothesize that a combination of an epigenetic modulator, vorinostat, along with rosiglitazone can impart improved gene expression of neurotrophic factors and attenuate biochemical and cellular alteration associated with AD mainly by loading these drugs in a surface modified nanocarrier system for enhanced bioavailability and enhanced therapeutic efficacy. Hence, in this study, rosiglitazone and vorinostat were loaded onto a poloxamer stabilized polymeric nanocarrier system and administered to mice in the intracerebroventricular streptozotocin (3 mg/kg) induced model of AD. Treatment with the free drug combination (rosiglitazone 5 mg/kg, vorinostat 25 mg/kg) for 3 weeks attenuated the behavioral, biochemical, and cellular alterations as compared to either treatment alone (rosiglitazone 10 mg/kg, vorinostat 50 mg/kg). Further, the coencapsulated nanoformulation (rosiglitazone 5 mg/kg, vorinostat 25 mg/kg) exerted better neuroprotective efficacy than the free drug combination as evidenced by improved behavioral outcome, reduced oxidative stress, and elevated levels of neurotrophic factors. In conclusion, the synergistic neuroprotective efficacy of rosiglitazone and vorinostat has been increased through the poloxamer stabilized polymeric nanocarrier system.
33860663	44	57	Rosiglitazone	Chemical	MESH:D000077154
33860663	62	72	Vorinostat	Chemical	MESH:D000077337
33860663	89	103	Streptozotocin	Chemical	MESH:D013311
33860663	112	116	Mice	Species	10090
33860663	126	143	Alzheimer Disease	Disease	MESH:D000544
33860663	240	257	Alzheimer disease	Disease	MESH:D000544
33860663	259	261	AD	Disease	MESH:D000544
33860663	336	349	rosiglitazone	Chemical	MESH:D000077154
33860663	477	487	vorinostat	Chemical	MESH:D000077337
33860663	500	513	rosiglitazone	Chemical	MESH:D000077154
33860663	640	642	AD	Disease	MESH:D000544
33860663	800	813	rosiglitazone	Chemical	MESH:D000077154
33860663	818	828	vorinostat	Chemical	MESH:D000077337
33860663	848	857	poloxamer	Chemical	MESH:D020442
33860663	918	922	mice	Species	10090
33860663	954	968	streptozotocin	Chemical	MESH:D013311
33860663	996	998	AD	Disease	MESH:D000544
33860663	1042	1055	rosiglitazone	Chemical	MESH:D000077154
33860663	1065	1075	vorinostat	Chemical	MESH:D000077337
33860663	1202	1215	rosiglitazone	Chemical	MESH:D000077154
33860663	1226	1236	vorinostat	Chemical	MESH:D000077337
33860663	1293	1306	rosiglitazone	Chemical	MESH:D000077154
33860663	1316	1326	vorinostat	Chemical	MESH:D000077337
33860663	1583	1596	rosiglitazone	Chemical	MESH:D000077154
33860663	1601	1611	vorinostat	Chemical	MESH:D000077337
33860663	1643	1652	poloxamer	Chemical	MESH:D020442
33860663	Negative_Correlation	MESH:D000077337	MESH:D000544
33860663	Positive_Correlation	MESH:D013311	MESH:D000544
33860663	Negative_Correlation	MESH:D000077154	MESH:D000544
33860663	Cotreatment	MESH:D000077154	MESH:D000077337
33860663	Association	MESH:D000077337	MESH:D020442
33860663	Association	MESH:D000077154	MESH:D020442

